<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103503</url>
  </required_header>
  <id_info>
    <org_study_id>Plexa Registry</org_study_id>
    <nct_id>NCT03103503</nct_id>
  </id_info>
  <brief_title>Plexa ICD Lead Registry</brief_title>
  <official_title>Plexa ICD Lead Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to confirm the long-term safety and reliability of&#xD;
      BIOTRONIK's Plexa ICD lead.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Collection of long term lead performance is being transferred to an alternate data collection&#xD;
    methodology.&#xD;
  </why_stopped>
  <start_date type="Actual">May 18, 2017</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">September 27, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Percentage of Subjects Free From Plexa Lead Related Adverse Events</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Evaluate the percentage of subjects without an adverse event related to the Plexa lead through study termination. The endpoint is analyzed as the adverse event free-rate. All protocol defined adverse events that occurred more than 30 days after implant and determined to be related to the Plexa lead plus required invasive intervention to resolve or were related to a lead integrity or clinical performance issue were included. Events meeting this criteria but occurring within 30 days were also included except for lead dislodgement, high pacing threshold, failure to capture, or intermittent capture.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plexa Lead Safety-Individual Adverse Events</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Evaluate the individual types of adverse events contributing to primary outcome measure 'Percentage of Subjects Free From Plexa Lead Related Adverse Events'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing Threshold Measurements for the Plexa Lead Through Study Termination</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Pacing threshold measurements at pulse width of 0.4 for the Plexa leads at completed follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensing Measurements for the Plexa Lead Through Study Termination</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Sensing measurements for the Plexa leads at completed follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing Impedance Measurements for the Plexa Lead Through Study Termination</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Pacing impedance measurements for the Plexa leads at completed follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock Impedance for the Plexa Lead Through Study Termination</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Shock impedance measurements for the Plexa leads at completed follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Free From Protocol Defined Adverse Events</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Evaluate the percentage of subjects without a protocol defined and clinical event committee adjudicated adverse event, excluding events included in the primary outcome 'Percentage of Subjects Free From Plexa Lead Related Adverse Events', through study termination. Lead dislodgements, high pacing threshold, failure to capture, and intermittent capture related to the Plexa lead that occurred less than or equal to 30 days after lead implant or a lead revision procedure are included here. The endpoint is analyzed as the adverse event free-rate.</description>
  </secondary_outcome>
  <enrollment type="Actual">901</enrollment>
  <condition>Implantable Defibrillator User</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The subject selected for participation should be from the investigator's general patient&#xD;
        population according to the inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successfully implanted with a BIOTRONIK ICD or CRT-D compatible system along with the&#xD;
             Plexa lead no more than 30 days prior to consent&#xD;
&#xD;
          -  Able to understand the nature of the registry and provide informed consent&#xD;
&#xD;
          -  Available for follow-up visits on a regular basis at the study site for the expected 5&#xD;
             years of follow-up&#xD;
&#xD;
          -  Accepts BIOTRONIK Home MonitoringÂ® concept&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in any investigational cardiac device trial&#xD;
&#xD;
          -  Enrolled in BIOTRONIK's QP ExCELs lead study&#xD;
&#xD;
          -  Planned cardiac surgical procedures or interventional measures within the next 6&#xD;
             months&#xD;
&#xD;
          -  Expected to receive heart transplantation or ventricular assist device within 1 year&#xD;
&#xD;
          -  Life expectancy of less than 1 year&#xD;
&#xD;
          -  Patients reporting pregnancy at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Hospital Research Office</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey S Goodman MD</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Desert Cardiology</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Health Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cardiology Consultants</name>
      <address>
        <city>Alton</city>
        <state>Illinois</state>
        <zip>62002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Cardiology</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Integrity LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Light Cardiology</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Heart</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Heart and Vascular</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gateway Cardiovascular Research Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Heart and Vascular</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Clinic Cardiology</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Institute Cardiology</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Cardiology</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arrhythmia Institute</name>
      <address>
        <city>Newtown</city>
        <state>Pennsylvania</state>
        <zip>18940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Cardiology</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Heart Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Cardiology Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates Ltd</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03103503/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIOTRONIK Plexa ICD Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="901"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="901"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Plexa Lead or Pulse Generator Extraction</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closure</title>
              <participants_list>
                <participants group_id="P1" count="757"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIOTRONIK Plexa ICD Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="901"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="894"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.35" spread="12.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="894"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement.</population>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="874"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Data collected and analyzed when available, not all subjects had data available for this measurement.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="880"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207.2" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Free From Plexa Lead Related Adverse Events</title>
        <description>Evaluate the percentage of subjects without an adverse event related to the Plexa lead through study termination. The endpoint is analyzed as the adverse event free-rate. All protocol defined adverse events that occurred more than 30 days after implant and determined to be related to the Plexa lead plus required invasive intervention to resolve or were related to a lead integrity or clinical performance issue were included. Events meeting this criteria but occurring within 30 days were also included except for lead dislodgement, high pacing threshold, failure to capture, or intermittent capture.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Free From Plexa Lead Related Adverse Events</title>
          <description>Evaluate the percentage of subjects without an adverse event related to the Plexa lead through study termination. The endpoint is analyzed as the adverse event free-rate. All protocol defined adverse events that occurred more than 30 days after implant and determined to be related to the Plexa lead plus required invasive intervention to resolve or were related to a lead integrity or clinical performance issue were included. Events meeting this criteria but occurring within 30 days were also included except for lead dislodgement, high pacing threshold, failure to capture, or intermittent capture.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="99.49" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plexa Lead Safety-Individual Adverse Events</title>
        <description>Evaluate the individual types of adverse events contributing to primary outcome measure 'Percentage of Subjects Free From Plexa Lead Related Adverse Events'</description>
        <time_frame>Up to 2.5 years</time_frame>
        <population>No primary outcome adverse events were reported; therefore, there are no individual events to be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Plexa Lead Safety-Individual Adverse Events</title>
          <description>Evaluate the individual types of adverse events contributing to primary outcome measure 'Percentage of Subjects Free From Plexa Lead Related Adverse Events'</description>
          <population>No primary outcome adverse events were reported; therefore, there are no individual events to be analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pacing Threshold Measurements for the Plexa Lead Through Study Termination</title>
        <description>Pacing threshold measurements at pulse width of 0.4 for the Plexa leads at completed follow-up visits.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Threshold Measurements for the Plexa Lead Through Study Termination</title>
          <description>Pacing threshold measurements at pulse width of 0.4 for the Plexa leads at completed follow-up visits.</description>
          <units>V</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>visits with measurement</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>visits with measurement</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensing Measurements for the Plexa Lead Through Study Termination</title>
        <description>Sensing measurements for the Plexa leads at completed follow-up visits.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensing Measurements for the Plexa Lead Through Study Termination</title>
          <description>Sensing measurements for the Plexa leads at completed follow-up visits.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>visits with measurement</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>visits with measurement</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3746"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.88" spread="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pacing Impedance Measurements for the Plexa Lead Through Study Termination</title>
        <description>Pacing impedance measurements for the Plexa leads at completed follow-up visits.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Pacing Impedance Measurements for the Plexa Lead Through Study Termination</title>
          <description>Pacing impedance measurements for the Plexa leads at completed follow-up visits.</description>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>visits with measurement</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>visits with measurement</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3925"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567.1" spread="111.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shock Impedance for the Plexa Lead Through Study Termination</title>
        <description>Shock impedance measurements for the Plexa leads at completed follow-up visits.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Shock Impedance for the Plexa Lead Through Study Termination</title>
          <description>Shock impedance measurements for the Plexa leads at completed follow-up visits.</description>
          <units>ohms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>visits with measurement</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>visits with measurement</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3913"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Free From Protocol Defined Adverse Events</title>
        <description>Evaluate the percentage of subjects without a protocol defined and clinical event committee adjudicated adverse event, excluding events included in the primary outcome 'Percentage of Subjects Free From Plexa Lead Related Adverse Events', through study termination. Lead dislodgements, high pacing threshold, failure to capture, and intermittent capture related to the Plexa lead that occurred less than or equal to 30 days after lead implant or a lead revision procedure are included here. The endpoint is analyzed as the adverse event free-rate.</description>
        <time_frame>Up to 2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIOTRONIK Plexa ICD Lead</title>
            <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Free From Protocol Defined Adverse Events</title>
          <description>Evaluate the percentage of subjects without a protocol defined and clinical event committee adjudicated adverse event, excluding events included in the primary outcome 'Percentage of Subjects Free From Plexa Lead Related Adverse Events', through study termination. Lead dislodgements, high pacing threshold, failure to capture, and intermittent capture related to the Plexa lead that occurred less than or equal to 30 days after lead implant or a lead revision procedure are included here. The endpoint is analyzed as the adverse event free-rate.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="901"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.12" lower_limit="93.49" upper_limit="96.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Though study exit or study termination, an average of 1.1 years</time_frame>
      <desc>Serious adverse events were defined according to ISO14155.</desc>
      <group_list>
        <group group_id="E1">
          <title>BIOTRONIK Plexa ICD Lead</title>
          <description>Subjects consented and implanted with a BIOTRONIK ICD or CRT-D pulse generator and a Plexa lead.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>LV lead related high pacing threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>LV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related other: high defibrillation threshold.no evidence for lead malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RA lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related high pacing threshold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related intermittent capture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related lead impedance out of range, high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related lead undersensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Twiddler's syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Pulmonary Emboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Loose set-screw</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Non-healing pocket dehiscence requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock during implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Operation wound bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Venous occlusion associated with the implant procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>LV lead related extracardiac stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>LV lead related lead impedance out of range, high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RV lead related other: positional atrial undersensing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RA lead related lead dislodgement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>RA lead related no capture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Non-healing pocket dehiscence requiring intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Slow wound healing, no sign for infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="901"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Studies Engineer Manager</name_or_title>
      <organization>BIOTRONIK</organization>
      <phone>800-547-0394</phone>
      <email>crystal.miller@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

